Acurx Pharmaceuticals, Inc.
Data quality: 83%
ACXP
Nasdaq
Manufacturing
Chemicals
$2.68
▼
$0.28
(-9.39%)
Mkt Cap: 7.66 M
Price
$2.68
Mkt Cap
7.66 M
Day Range
$2.66 — $2.97
52-Week Range
$1.33 — $21.00
Volume
155,547
Open $2.93
50D / 200D Avg
$2.91
7.77% below
50D / 200D Avg
$4.83
44.51% below
Quick Summary
Key Takeaways
Negative free cash flow of -6.79 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-221.19%
Below sector avg (-53.41%)
ROIC-178.80%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Valuation
PE (TTM)
-0.96
Above sector avg (-1.48)
P/B Ratio2.11
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.0 | -1.5 |
| P/B | 2.1 | 1.6 |
| ROE % | -221.2 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -7.97 M |
| ROE | -221.19% | ROA | -130.49% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -6.79 M |
| ROIC | -178.80% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | N/A | Tangible Book Value | 3.64 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0.96 | Forward P/E | N/A |
| P/B Ratio | 2.11 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -88.65% | ||
| Market Cap | 7.66 M | Enterprise Value | 7.66 M |
| Per Share | |||
| EPS (Diluted TTM) | -5.32 | Revenue / Share | N/A |
| FCF / Share | -2.38 | OCF / Share | -2.38 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 85.20% |
| SBC-Adj. FCF | -8.09 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -7.97 M | -14.10 M | -14.58 M | -12.09 M | -12.75 M |
| EPS (Diluted) | -5.32 | -0.87 | -1.15 | -1.12 | -1.49 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -8.09 M | — | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 1.83 M | 5.40 M | 6.04 M | 4.75 M | 2.03 M |
| SG&A Expenses | — | — | — | — | 208,270.0 |
| D&A | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Income Tax | — | — | — | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7.69 M | 3.86 M | 7.71 M | 9.38 M | 13.25 M |
| Total Liabilities | 2.42 M | 3.24 M | 3.04 M | 2.06 M | 843,909.0 |
| Shareholders' Equity | 5.27 M | 615,121.0 | 4.67 M | 7.32 M | — |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | — | — | — |
| Current Assets | — | — | — | — | — |
| Current Liabilities | 2.42 M | 3.24 M | 3.04 M | 2.06 M | 843,909.0 |
{"event":"ticker_viewed","properties":{"ticker":"ACXP","listing_kind":"stock","pathname":"/stocks/acxp","exchange":"Nasdaq","country":"US"}}